Water Drops on Burning Rocks

Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics

Retrieved on: 
Monday, October 30, 2023
MSA, NMPA, TP53, Hope, Boehringer Ingelheim, National Medical Products Administration, Master service agreement, Research, Rock, Partnership, Cancer, LSE, BTC, Safety, Patient, Pharmaceutical industry, Water Drops on Burning Rocks

GUANGZHOU, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that the Company and Boehringer Ingelheim officially have signed the Master Service Agreement (MSA) in the field of oncology companion diagnostics.

Key Points: 
  • GUANGZHOU, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that the Company and Boehringer Ingelheim officially have signed the Master Service Agreement (MSA) in the field of oncology companion diagnostics.
  • This partnership will primarily focus on advancing the clinical trials related to Boehringer Ingelheim's MDM2-p53 antagonist, brigimadlin (BI 907828), and the development of companion diagnostic products in China.
  • Mr. Yusheng Han, Founder and CEO of Burning Rock, expressed, “We are delighted to establish a deep collaboration in companion diagnostics with Boehringer Ingelheim.
  • Burning Rock has a comprehensive layout and supports companion diagnostics development with a global perspective for pharmaceutical companies.

Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test

Retrieved on: 
Monday, October 16, 2023
Food, Annals of Oncology, NGS, Risk, National Medical Products Administration, Ageing, Cancer, Rock, US Foods, FDA, LSE, Nucleic acid thermodynamics, NMPA, US FDA, Medical imaging, Water Drops on Burning Rocks

GUANGZHOU, China, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that followed an earlier Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for its OverC™ Multi-Cancer Detection Blood Test (MCDBT) in January 2023, its OverC™ MCDBT has been granted Breakthrough Device Designation by the China National Medical Products Administration(NMPA), which represents the only test globally that has received Breakthrough Device Designation from both US FDA and China NMPA.

Key Points: 
  • GUANGZHOU, China, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that followed an earlier Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for its OverC™ Multi-Cancer Detection Blood Test (MCDBT) in January 2023, its OverC™ MCDBT has been granted Breakthrough Device Designation by the China National Medical Products Administration(NMPA), which represents the only test globally that has received Breakthrough Device Designation from both US FDA and China NMPA.
  • OverC™ MCDBT is intended for early detection of multiple cancer types in adults of either sex, aged 50-75 years old, at average risk for cancer.
  • Mr. Yusheng Han, founder and CEO of Burning Rock, said, “We are very inspired that our multi-cancer early detection product has received recognition from both US and China regulatory authorities.
  • We obtained our first Breakthrough Device Designation from China NMPA in 2016 for NGS-based therapy selection test, and the China NMPA Breakthrough Device Designation granted for OverC™ MCDBT would pave the way for a clearer registration path through confirmative performance validation and utility establishment.

Burning Rock Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 31, 2023
LSE, The New England Journal of Medicine, Science Translational Medicine, Water Drops on Burning Rocks, Progression-free survival, Marketing, NGS, Fulvestrant, Breast, Research, ID, Precision, AstraZeneca, Liver cancer, ASCO, HR, US, Hospital, Patient, Organoid, Investment, Drug combination, Webcast, Depreciation, CDX, Ovarian cancer, Safety, Disease, Pharmaceutical industry, Fine chemical, Cryptocurrency

GUANGZHOU, China, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2023.

Key Points: 
  • GUANGZHOU, China, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2023.
  • Presented study results on extensive-stage small-cell lung cancer and ovarian cancer at the ASCO in June 2023.
  • Results of the study “Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology” were published at the Science Translational Medicine in August 2023.
  • Burning Rock will host a conference call to discuss the second quarter 2023 financial results at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong time) on August 31, 2023.

SEABOURN'S NEW ULTRA-LUXURY EXPEDITION SHIP, SEABOURN PURSUIT, UNVEILS MASTERFULLY CURATED ART COLLECTION, CUSTOM WORKS INSPIRED BY THE SPIRIT OF EXPLORATION AND WONDROUS GLOBAL DISCOVERIES

Retrieved on: 
Wednesday, August 30, 2023
Constellation, DNA, Human, Travel, Painting, Magic, Blue–green distinction in language, Sculpture, Perception, Light, Seabourn Venture, Table tennis rubber, Moon, Flower, Atrium, Sky Bar, Ship, Amazon, Murano, Ice, Beauty, Animal, Gold, Water Drops on Burning Rocks, Collection, River, Double decker, Water, Restaurant, Glass, PVC, Lake, Shipbuilding, Entertainment, Pottery, Interior design, Seabourn Cruise Line, Arctic

SEATTLE, Aug. 30, 2023 /PRNewswire/ -- Seabourn, the leader in ultra-luxury ocean voyages and expedition travel, and renowned for creating exquisitely designed spaces aboard its ships that exemplify themes of exploration and adventure, has unveiled an extraordinary collection of custom art on board Seabourn Pursuit, its newly launched, purpose-built expedition vessel. The extensive, permanent installation includes more than 700 artworks and takes guests on a curated journey across the seven seas.

Key Points: 
  • The extensive, permanent installation includes more than 700 artworks and takes guests on a curated journey across the seven seas.
  • Seabourn's expedition vessels, Seabourn Venture and Seabourn Pursuit, bear strong resemblance as sister ships that share the same DNA in design.
  • However, art stands out as one of the most prominent and character-defining points of differentiation between them.
  • It features custom art that masterfully celebrates the wonders of our planet and the great explorers of our time, infused with geographic inspiration.

Burning Rock Announces Resignation and Appointment of Directors

Retrieved on: 
Wednesday, June 28, 2023
Emperor Chūai, NGS, MRD, LSE, Patient, Physician, Management, Water Drops on Burning Rocks

Mr. Yusheng Han, Burning Rock’s founder, chairman of the Board and chief executive officer, commented, “We would like to take this opportunity to thank Shannon for her high-impact service to Burning Rock since 2014.

Key Points: 
  • Mr. Yusheng Han, Burning Rock’s founder, chairman of the Board and chief executive officer, commented, “We would like to take this opportunity to thank Shannon for her high-impact service to Burning Rock since 2014.
  • Through her long tenure at Burning Rock, Shannon has played an instrumental role in building Burning Rock's product solutions, driving their adoption with leading physicians at industry-leading forums, and building our science team.
  • I am also proud of the talent that we have developed internally at Burning Rock.
  • I am proud of our collective achievements at Burning Rock and am highly confident of Burning Rock's future going forward.”

Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine

Retrieved on: 
Thursday, June 8, 2023
LSE, Progression-free survival, CGP, Fulvestrant, AstraZeneca, AKT1, PIK3CA, HR, Patient, PTEN, Breast cancer, Water Drops on Burning Rocks, Safety, Disease, Pharmaceutical industry

The study demonstrated that Capivasertib–fulvestrant combination therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone.

Key Points: 
  • The study demonstrated that Capivasertib–fulvestrant combination therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone.
  • In the study, Burning Rock's flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was used to determine activating mutations in PIK3CA and AKT1 and inactivating alterations in PTEN genes for patients enrolled in China.
  • We are proud to have supported our pharma client in such a high impact study, after a rigorous test solution provider evaluation process.
  • [1] Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer.

Burning Rock Reports First Quarter 2023 Financial Results

Retrieved on: 
Tuesday, May 30, 2023
LSE, Advertising, AACR, Travel, Water Drops on Burning Rocks, Methylation, Marketing, Cholangiocarcinoma, NGS, COVID-19, Lung cancer, Prognosis, Research, NSCLC, ID, PPV, MRD, US, NPV, Patient, Investment, Webcast, Depreciation, Growth, Neoplasm, Clothing, Medical imaging, Pharmaceutical industry, Cryptocurrency, Palladium

GUANGZHOU, China, May 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2023.

Key Points: 
  • GUANGZHOU, China, May 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2023.
  • Results of the MEDAL (MEthylation Based Dynamic Analysis for Lung Cancer) study were published at the American Association for Cancer Research Annual Meeting 2023 (“AACR 2023”).
  • The results of the clinical performance of brPROPHET™ in patients with resectable gastric cancer and biliary tract cancer were also released at AACR 2023.
  • Burning Rock will host a conference call to discuss the first quarter 2023 financial results at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong time) on May 30, 2023.

Burning Rock provides an update on 2022 revenue guidance

Retrieved on: 
Wednesday, January 18, 2023
Water Drops on Burning Rocks, LSE, Growth, NGS, Renewable energy

This represents an upward revision compared with the Company’s previous guidance on the full-year revenue growth of 5% as announced on November 15, 2022 in its financial results for the third quarter of 2022.

Key Points: 
  • This represents an upward revision compared with the Company’s previous guidance on the full-year revenue growth of 5% as announced on November 15, 2022 in its financial results for the third quarter of 2022.
  • The upward revision of revenue guidance was primarily driven by a better fourth quarter performance compared to the Company’s estimation underlying its previous guidance back in November.
  • Burning Rock expects to announce its fourth quarter and full year 2022 results in March 2023.
  • Burning Rock has not completed the preparation of its financial statements for the fourth quarter or full year 2022.

Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test

Retrieved on: 
Tuesday, January 3, 2023
Cancer, Ovarian cancer, Ageing, Food, Lung, Area studies, NGS, DNA, ASCO, Risk, Liquid biopsy, Disease, Tissue, Patient, Nucleic acid thermodynamics, US Foods, Machine learning, FDA, Quality of life, DNA methylation, ESMO, Pancreatic cancer, Breakthrough, Survival, Diagnosis, Liver, Medical imaging, Water Drops on Burning Rocks

Under the FDA’s Breakthrough Devices Program, the Breakthrough Device Designation is granted to certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions such as cancer.

Key Points: 
  • Under the FDA’s Breakthrough Devices Program, the Breakthrough Device Designation is granted to certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions such as cancer.
  • In May 2022, Burning Rock received CE mark for its OverC™ MCDBT manufactured in both the US and China facilities.
  • Today, the FDA Breakthrough Device Designation granted for OverC™ MCDBT would pave the way for a clearer registration path through confirmative performance validation and utility establishment.
  • Mr. Yusheng Han, founder and CEO of Burning Rock, said, “We are very excited that our cfDNA methylation multi-cancer early detection technology has received FDA Breakthrough Device Designation.

Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test

Retrieved on: 
Tuesday, January 3, 2023
NGS, Quality of life, US Foods, Patient, ESMO, Food, Tissue, ASCO, Liver, Liquid biopsy, Disease, Diagnosis, Risk, FDA, Ovarian cancer, Area studies, Breakthrough, DNA, Pancreatic cancer, Nucleic acid thermodynamics, DNA methylation, Cancer, Survival, Lung, Ageing, Machine learning, Medical imaging, Water Drops on Burning Rocks

Under the FDA's Breakthrough Devices Program, the Breakthrough Device Designation is granted to certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions such as cancer.

Key Points: 
  • Under the FDA's Breakthrough Devices Program, the Breakthrough Device Designation is granted to certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions such as cancer.
  • In May 2022, Burning Rock received CE mark for its OverC™ MCDBT manufactured in both the US and China facilities.
  • Today, the FDA Breakthrough Device Designation granted for OverC™ MCDBT would pave the way for a clearer registration path through confirmative performance validation and utility establishment.
  • Mr. Yusheng Han, founder and CEO of Burning Rock, said, "We are very excited that our cfDNA methylation multi-cancer early detection technology has received FDA Breakthrough Device Designation.